1
|
Qiao Z, Tang S, Guan J, Yin Z, Zhu C, Zhou Q, Shao L. Design and development of selective competitive fluorescent ligands for the detection and visualization of Kv7.2/7.3 in vitro. Chem Commun (Camb) 2022; 58:3791-3794. [PMID: 35230378 DOI: 10.1039/d2cc00372d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
A series of specific and potent fluorescent ligands were developed for labelling and visualizing Kv7.2/7.3 based molecular rotation restriction. Probes 21b and 24a were found to be safe and convenient...
Collapse
Affiliation(s)
- Zhen Qiao
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.
| | - Siyuan Tang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.
| | - Jialiang Guan
- The Department of Emergency Internal Medicine, The Affiliated Hospital of Qingdao University, Shandong 266001, China
| | - Zhengji Yin
- Departments of Pharmacology, School of Pharmacy, Qingdao University Medical College, #1 Ningde Road, Qingdao 266073, China
| | - Chao Zhu
- The Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Shandong 266001, China
| | - Qiqi Zhou
- Department of Pharmacology, Qilu Medical University, Zibo, Shandong 255300, China.
| | - Liming Shao
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.
| |
Collapse
|
2
|
Progression of KCNQ4 related genetic hearing loss: a narrative review. JOURNAL OF BIO-X RESEARCH 2021. [DOI: 10.1097/jbr.0000000000000112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
3
|
Borgini M, Mondal P, Liu R, Wipf P. Chemical modulation of Kv7 potassium channels. RSC Med Chem 2021; 12:483-537. [PMID: 34046626 PMCID: PMC8128042 DOI: 10.1039/d0md00328j] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 12/01/2020] [Indexed: 01/10/2023] Open
Abstract
The rising interest in Kv7 modulators originates from their ability to evoke fundamental electrophysiological perturbations in a tissue-specific manner. A large number of therapeutic applications are, in part, based on the clinical experience with two broad-spectrum Kv7 agonists, flupirtine and retigabine. Since precise molecular structures of human Kv7 channel subtypes in closed and open states have only very recently started to emerge, computational studies have traditionally been used to analyze binding modes and direct the development of more potent and selective Kv7 modulators with improved safety profiles. Herein, the synthetic and medicinal chemistry of small molecule modulators and the representative biological properties are summarized. Furthermore, new therapeutic applications supported by in vitro and in vivo assay data are suggested.
Collapse
Affiliation(s)
- Matteo Borgini
- Department of Chemistry, University of Pittsburgh Pittsburgh PA 15260 USA
| | - Pravat Mondal
- Department of Chemistry, University of Pittsburgh Pittsburgh PA 15260 USA
| | - Ruiting Liu
- Department of Chemistry, University of Pittsburgh Pittsburgh PA 15260 USA
| | - Peter Wipf
- Department of Chemistry, University of Pittsburgh Pittsburgh PA 15260 USA
| |
Collapse
|
4
|
Activation of KCNQ4 as a Therapeutic Strategy to Treat Hearing Loss. Int J Mol Sci 2021; 22:ijms22052510. [PMID: 33801540 PMCID: PMC7958948 DOI: 10.3390/ijms22052510] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 02/16/2021] [Accepted: 02/22/2021] [Indexed: 12/14/2022] Open
Abstract
Potassium voltage-gated channel subfamily q member 4 (KCNQ4) is a voltage-gated potassium channel that plays essential roles in maintaining ion homeostasis and regulating hair cell membrane potential. Reduction of the activity of the KCNQ4 channel owing to genetic mutations is responsible for nonsyndromic hearing loss, a typically late-onset, initially high-frequency loss progressing over time. In addition, variants of KCNQ4 have also been associated with noise-induced hearing loss and age-related hearing loss. Therefore, the discovery of small compounds activating or potentiating KCNQ4 is an important strategy for the curative treatment of hearing loss. In this review, we updated the current concept of the physiological role of KCNQ4 in the inner ear and the pathologic mechanism underlying the role of KCNQ4 variants with regard to hearing loss. Finally, we focused on currently developed KCNQ4 activators and their pros and cons, paving the way for the future development of specific KCNQ4 activators as a remedy for hearing loss.
Collapse
|
5
|
Wilenkin B, Burris KD, Eastwood BJ, Sher E, Williams AC, Priest BT. Development of an Electrophysiological Assay for Kv7 Modulators on IonWorks Barracuda. Assay Drug Dev Technol 2020; 17:310-321. [PMID: 31634018 DOI: 10.1089/adt.2019.942] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Relief from chronic pain continues to represent a large unmet need. The voltage-gated potassium channel Kv7.2/7.3, also known as KCNQ2/3, is a key contributor to the control of resting membrane potential and excitability in nociceptive neurons and represents a promising target for potential therapeutics. In this study, we present a medium throughput electrophysiological assay for the identification and characterization of modulators of Kv7.2/7.3 channels, using the IonWorks Barracuda™ automated voltage clamp platform. The assay combines a family of voltage steps used to construct conductance curves with a unique analysis method. Kv7.2/7.3 modulators shift the activation voltage and/or change the maximal conductance of the current, and both parameters have been used to quantify compound mediated effects. Both effects are expected to modulate neuronal excitability in vivo. The analysis method described assigns a single potency value that combines changes in activation voltage and maximal conductance and is expected to predict compound mediated changes in excitability.
Collapse
Affiliation(s)
- Benjamin Wilenkin
- Department of Quantitative Biology, Eli Lilly and Company, Indianapolis, Indiana
| | - Kevin D Burris
- Department of Quantitative Biology, Eli Lilly and Company, Indianapolis, Indiana
| | - Brian J Eastwood
- Department of Statistics, Eli Lilly and Company, Indianapolis, Indiana
| | - Emanuele Sher
- Department of Discovery Pain Group, Eli Lilly and Company, Indianapolis, Indiana
| | - Andrew C Williams
- Department of Medicinal Chemistry, Eli Lilly and Company, Indianapolis, Indiana
| | - Birgit T Priest
- Department of Quantitative Biology, Eli Lilly and Company, Indianapolis, Indiana
| |
Collapse
|
6
|
Abstract
The highly structurally similar drugs flupirtine and retigabine have been regarded as safe and effective for many years but lately they turned out to exert intolerable side effects. While the twin molecules share the mode of action, both stabilize the open state of voltage-gated potassium channels, the form and severity of adverse effects is different. The analgesic flupirtine caused drug-induced liver injury in rare but fatal cases, whereas prolonged use of the antiepileptic retigabine led to blue tissue discoloration. Because the adverse effects seem unrelated to the mode of action, it is likely, that both drugs that occupied important therapeutic niches, could be replaced. Reasons for the clinically relevant toxicity will be clarified and future substitutes for these drugs presented in this review.
Collapse
|
7
|
Barrese V, Stott JB, Greenwood IA. KCNQ-Encoded Potassium Channels as Therapeutic Targets. Annu Rev Pharmacol Toxicol 2018; 58:625-648. [DOI: 10.1146/annurev-pharmtox-010617-052912] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | - Iain A. Greenwood
- Vascular Biology Research Centre, Molecular and Clinical Sciences Institute, St George's, University of London, London, SW17 0RE, United Kingdom;, ,
| |
Collapse
|
8
|
Al-Sabi A, Daly D, Hoefer P, Kinsella GK, Metais C, Pickering M, Herron C, Kaza SK, Nolan K, Dolly JO. A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction. J Med Chem 2017; 60:2245-2256. [PMID: 28225274 DOI: 10.1021/acs.jmedchem.6b01262] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
K+ channels containing Kv1.1 α subunits, which become prevalent at internodes in demyelinated axons, may underlie their dysfunctional conduction akin to muscle weakness in multiple sclerosis. Small inhibitors were sought with selectivity for the culpable hyper-polarizing K+ currents. Modeling of interactions with the extracellular pore in a Kv1.1-deduced structure identified diaryldi(2-pyrrolyl)methane as a suitable scaffold with optimized alkyl ammonium side chains. The resultant synthesized candidate [2,2'-((5,5'(di-p-topyldiaryldi(2-pyrrolyl)methane)bis(2,2'carbonyl)bis(azanediyl)) diethaneamine·2HCl] (8) selectively blocked Kv1.1 channels (IC50 ≈ 15 μM) recombinantly expressed in mammalian cells, induced a positive shift in the voltage dependency of K+ current activation, and slowed its kinetics. It preferentially inhibited channels containing two or more Kv1.1 subunits regardless of their positioning in concatenated tetramers. In slices of corpus callosum from mice subjected to a demyelination protocol, this novel inhibitor improved neuronal conduction, highlighting its potential for alleviating symptoms in multiple sclerosis.
Collapse
Affiliation(s)
| | | | | | - Gemma K Kinsella
- School of Food Science and Environmental Health, College of Sciences and Health, Dublin Institute of Technology , Cathal Brugha Street, Dublin 1, Ireland
| | | | - Mark Pickering
- UCD School of Medicine, University College Dublin , Dublin, Ireland
| | - Caroline Herron
- School of Biomolecular and Biomed Science, Conway Institute , Belfield, Dublin 4, Ireland
| | | | | | | |
Collapse
|
9
|
Wang L, Zellmer SG, Printzenhoff DM, Castle NA. Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation. Br J Pharmacol 2015. [PMID: 26220736 DOI: 10.1111/bph.13259] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND AND PURPOSE Aryl sulfonamide Nav 1.3 or Nav 1.7 voltage-gated sodium (Nav ) channel inhibitors interact with the Domain 4 voltage sensor domain (D4 VSD). During studies to better understand the structure-activity relationship of this interaction, an additional mode of channel modulation, specifically slowing of inactivation, was revealed by addition of a single methyl moiety. The objective of the current study was to determine if these different modulatory effects are mediated by the same or distinct interactions with the channel. EXPERIMENTAL APPROACH Electrophysiology and site-directed mutation were used to compare the effects of PF-06526290 and its desmethyl analogue PF-05661014 on Nav channel function. KEY RESULTS PF-05661014 selectively inhibits Nav 1.3 versus Nav 1.7 currents by stabilizing inactivated channels via interaction with D4 VSD. In contrast, PF-06526290, which differs from PF-05661014 by a single methyl group, exhibits a dual effect. It greatly slows inactivation of Nav channels in a subtype-independent manner. However, upon prolonged depolarization to induce inactivation, PF-06526290 becomes a Nav subtype selective inhibitor similar to PF-05661014. Mutation of the D4 VSD modulates inhibition of Nav 1.3 or Nav 1.7 by both PF-05661014 and PF-06526290, but has no effect on the inactivation slowing produced by PF-06526290. This finding, along with the absence of functional inhibition of PF-06526290-induced inactivation slowing by PF-05661014, suggests that distinct interactions underlie the two modes of Nav channel modulation. CONCLUSIONS AND IMPLICATIONS Addition of a methyl group to a Nav channel inhibitor introduces an additional mode of gating modulation, implying that a single compound can affect sodium channel function in multiple ways.
Collapse
|
10
|
Crestey F, Frederiksen K, Jensen HS, Dekermendjian K, Larsen PH, Bastlund JF, Lu D, Liu H, Yang CR, Grunnet M, Svenstrup N. Identification and electrophysiological evaluation of 2-methylbenzamide derivatives as Nav1.1 modulators. ACS Chem Neurosci 2015; 6:1302-8. [PMID: 26114759 DOI: 10.1021/acschemneuro.5b00147] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Voltage-gated sodium channels (Nav) are crucial to the initiation and propagation of action potentials (APs) in electrically excitable cells, and during the past decades they have received considerable attention due to their therapeutic potential. Here, we report for the first time the synthesis and the electrophysiological evaluation of 16 ligands based on a 2-methylbenzamide scaffold that have been identified as Nav1.1 modulators. Among these compounds, N,N'-(1,3-phenylene)bis(2-methylbenzamide) (3a) has been selected and evaluated in ex-vivo experiments in order to estimate the activation impact of such a compound profile. It appears that 3a increases the Nav1.1 channel activity although its overall impact remains moderate. Altogether, our preliminary results provide new insights into the development of small molecule activators targeting specifically Nav1.1 channels to design potential drugs for treating CNS diseases.
Collapse
Affiliation(s)
- François Crestey
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| | - Kristen Frederiksen
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| | - Henrik S. Jensen
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| | - Kim Dekermendjian
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| | - Peter H. Larsen
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| | - Jesper F. Bastlund
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| | - Dunguo Lu
- ChemPartner Co.
Ltd., 998 Halei Road, Zhangjiang Hi-Tech
Park, Shanghai 201203, P. R. China
| | - Henry Liu
- ChemPartner Co.
Ltd., 998 Halei Road, Zhangjiang Hi-Tech
Park, Shanghai 201203, P. R. China
| | - Charles R. Yang
- ChemPartner Co.
Ltd., 998 Halei Road, Zhangjiang Hi-Tech
Park, Shanghai 201203, P. R. China
| | - Morten Grunnet
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| | - Niels Svenstrup
- Neuroscience Drug
Discovery, H. Lundbeck A/S, Ottiliavej
9, 2500 Valby, Denmark
| |
Collapse
|